Menu Search
Equities

Theralase Technologies Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
TTX:FRA

Theralase Technologies Inc

Actions
  • Price (EUR)0.171
  • Today's Change0.00 / 0.00%
  • Shares traded5.02k
  • 1 Year change-10.00%
  • Beta0.4762
Data delayed at least 15 minutes, as of Feb 16 2026 07:17 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which researches, develops, manufactures and distributes cool laser therapy systems to healthcare practitioners, predominantly for the healing of pain.

  • Revenue in CAD (TTM)1.00m
  • Net income in CAD-4.35m
  • Incorporated1989
  • Employees0.00
  • Location
    Theralase Technologies Inc41 Hollinger RoadTORONTO M4B 3G4CanadaCAN
  • Phone+1 (416) 699-5273
  • Fax+1 (416) 699-5250
  • Websitehttps://theralase.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.